Cargando…

IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events

Background: Immune-related cutaneous adverse events (ircAEs) are frequent and may reduce quality of life and consistent dosing. IL12/23 has been implicated in psoriasis, which is reminiscent of the psoriasiform/lichenoid ircAE phenotype. We report the use of ustekinumab as a therapeutic option. Meth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Stephanie L., Maier, Tara, Moy, Andrea P., Dusza, Stephen, Faleck, David M., Shah, Neil J., Lacouture, Mario E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674871/ https://www.ncbi.nlm.nih.gov/pubmed/38004414 http://dx.doi.org/10.3390/ph16111548

Ejemplares similares

Management of immune-related cutaneous adverse events with dupilumab
por: Kuo, Alyce Mei-Shiuan, et al.
Publicado: (2023)

Contribution of the Skin–Gut Axis to Immune-Related Adverse Events with Multi-System Involvement
por: Kuo, Alyce M., et al.
Publicado: (2022)

Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab
por: Pugliese, Daniela, et al.
Publicado: (2022)

Successful treatment with the IL12/IL23 antagonist ustekinumab in a patient with refractory Takayasu arteritis
por: Saur, Sebastian-Jonas, et al.
Publicado: (2021)

IL-12p40/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt
por: Fiechter, Renée H., et al.
Publicado: (2021)

Indirect Regulation and Equilibrium of p35 and p40 Subunits of Interleukin (IL)-12/23 by Ustekinumab in Psoriasis Treatment
por: Zhou, Jiong, et al.
Publicado: (2020)

Ustekinumab-induced subacute cutaneous lupus
por: Tierney, Emma, et al.
Publicado: (2019)

Sorption of Interleukins 12 and 23 Using the Developed Magnetocontrollable Ustekinumab-Based Sorbent
por: Gontar, I.P., et al.
Publicado: (2020)

Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer
por: Quatresooz, Pascale, et al.
Publicado: (2012)

Bullous Wells Syndrome Induced by Ustekinumab
por: Kim, Yeona, et al.
Publicado: (2023)

Blockade of IL-23: What is in the Pipeline?
por: Parigi, Tommaso Lorenzo, et al.
Publicado: (2022)

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
por: Koutruba, Nora, et al.
Publicado: (2010)

Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy
por: Huang, Yun-Han, et al.
Publicado: (2021)

Plurifocal cutaneous leishmaniasis during treatment with ustekinumab
por: Rakotonarivo, Louva, et al.
Publicado: (2018)

Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation
por: Murphy, Craig A., et al.
Publicado: (2003)

Paradoxical Flare of Psoriasis after Ustekinumab Therapy
por: Lee, Ho Yeol, et al.
Publicado: (2017)

Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results
por: Smolen, Josef S, et al.
Publicado: (2021)

Erythema multiforme after initiation of anti interleukin-12/23 (ustekinumab) treatment for plaque psoriasis
por: Burlando, Martina, et al.
Publicado: (2020)

Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection
por: vom Berg, Johannes, et al.
Publicado: (2013)

Evolution of IL-23 Blockade in Inflammatory Bowel Disease
por: Danese, Silvio, et al.
Publicado: (2022)

Manifestations of cutaneous mycobacterial infections in patients with inborn errors of IL-12/IL-23-IFNγ immunity
por: Dolezalova, Karolina, et al.
Publicado: (2022)

Multiple Lentigines Arising in Sites of Resolving Psoriatic Plaques after Treatment with Ustekinumab
por: Kim, Jeong Soo, et al.
Publicado: (2018)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

The First Case of Ustekinumab-Associated Hair Repigmentation and a Proposed Mechanism of Action
por: Park, Su Jung, et al.
Publicado: (2021)

Successful treatment of a child's pityriasis rubra pilaris (PRP) with ustekinumab and acitretin
por: Katharina, Medek, et al.
Publicado: (2022)

Adverse Events Associated With Anti-IL-23 Agents: Clinical Evidence and Possible Mechanisms
por: Ru, Yi, et al.
Publicado: (2021)

The Dichotomous Pattern of IL-12R and IL-23R Expression Elucidates the Role of IL-12 and IL-23 in Inflammation
por: Chognard, Gaëlle, et al.
Publicado: (2014)

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Bai, Fan, et al.
Publicado: (2019)

Systematic review: IL-12/23 or IL-23 antagonists and RTIs or ILD
Publicado: (2020)

IL-12– and IL-23–modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition
por: Kroenke, Mark A., et al.
Publicado: (2008)

Current Evidence for IL-17/23 Blockade for the Treatment of Lupus Nephritis
por: Santacruz, Juan Camilo, et al.
Publicado: (2021)

Association of ustekinumab and briakinumab with major adverse cardiovascular events: An appraisal of meta-analyses and industry sponsored pooled analyses to date
por: Tzellos, Thrasivoulos, et al.
Publicado: (2012)

Commensal-dependent expression of IL-25 regulates the IL-23–IL-17 axis in the intestine
por: Zaph, Colby, et al.
Publicado: (2008)

Hypersensitivity Reaction to Ustekinumab in Pediatric and Young Adult Inflammatory Bowel Disease Patients: A Case Series
por: Sunny, Julee, et al.
Publicado: (2022)

Regulation of Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-27
por: Xu, Mingli, et al.
Publicado: (2010)

To Evaluate the Role and Relevance of Cytokines IL-17, IL-18, IL-23 and TNF-α and Their Correlation with Disease Severity in Chronic Urticaria
por: Sharma, Preeti, et al.
Publicado: (2020)

IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease
por: Geremia, Alessandra, et al.
Publicado: (2011)

IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis
por: Wueest, Stephan, et al.
Publicado: (2021)

The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab
por: Chiu, Hsien-Yi, et al.
Publicado: (2015)

Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis
por: Conrad, Curdin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2ig6a2icvltrrpqrh8jd40ds6g